EUVIMEDEUVIMED entdecken
Crossref

Transfusion reactions after whole blood transfusion in Norway, 2021–2024: A report from the Norwegian Hemovigilance program

Bjarte Skoe Erikstein iD, Thomas Larsen Titze, Barbora Jacobsen, Tor Hervig, Are Engum, Torunn Oveland Apelseth iD, Øystein Flesland

Transfusion · 2026-06 · 66 (6) · 1099-1107

DOI: 10.1111/trf.70193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, online erschienen am 29.03.2026. Verfasst von Bjarte Skoe Erikstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Norwegian Medical Product Agency, Oslo, Norway. Hauptthemen laut MEDLINE: Transfusion Reaction, Blood Safety. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whole blood (WB) transfusion for major hemorrhage in Western civilian settings has seen a resurgence over the past two decades. This study aims to determine the rate and type of adverse reactions (ARs) following WB transfusion in Norway between 2021 and 2024. Study Design and Methods This retrospective quality surveillance study analyzed, validated, and aggregated all digital reports of ARs after WB transfusion submitted to the Norwegian Hemovigilance system.

Results

Seven ARs were identified, corresponding to an incidence rate of 2.53 per 1000 WB transfusions (7 per 2766 transfusions) or 0.253% (95% CI: 0.123%–0.521%). Three cases were classified as acute hemolytic transfusion reactions: one due to ABO minor incompatibility, one to anti‐Jk a , and one associated with an unidentified red blood cell alloantibody. One case involved respiratory distress and was diagnosed as transfusion‐associated dyspnea. Two reactions were allergic: one mild and one fulfilling the criteria for transfusion‐associated anaphylaxis. The most severe case involved cardiac arrest, probably due to hyperkalemia and hypocalcemia following massive transfusion, but the patient made a full recovery after defibrillation.

Discussion

These findings indicate that WB transfusion in Norway is safe. However, there are inherent risks for blood transfusion in general and also risks more specific to WB transfusion. These include the presence of red blood cell alloantibodies anti‐A and anti‐B combined with approximately 250 mL plasma from a single donor. Accurate and timely hemovigilance work is important to safeguard patient outcomes and provide a foundation for targeted risk mitigation strategies for WB transfusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transfusion ReactionBlood SafetyHumansNorwayRetrospective StudiesFemaleMaleMiddle AgedBlood Group IncompatibilityBlood TransfusionAdultAgedIsoantibodiesAnaphylaxis

Stichwörter der Autor:innen

LTOWBblood transfusionemergency medical serviceshemovigilancehyperkalemiatransfusion complicationtransfusion reactionwhole blood

Substanzen

Isoantibodies

Autor:innen und Institutionen

  • Norwegian Medical Product Agency, Oslo, Norway.
  • Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway.
  • Department of Laboratory Medicine, Vestre Viken Health Trust, Norway.
  • Department of Immunology and Transfusion Medicine, St. Olav University Hospital, Trondheim, Norway.
  • Stavanger University Hospital, Stavanger, Norway.
  • Norwegian Centre for Blood Preparedness, Bergen, Norway.

ORCID-Profile: Bjarte Skoe Erikstein, Torunn Oveland Apelseth

Zitieren

APA

Erikstein, B. S., Titze, T. L., Jacobsen, B., Hervig, T., Engum, A., Apelseth, T. O., & Flesland, Ø. (2026). Transfusion reactions after whole blood transfusion in Norway, 2021–2024: A report from the Norwegian Hemovigilance program. Transfusion, 66(6), 1099-1107. https://doi.org/10.1111/trf.70193

Vancouver

Erikstein BS, Titze TL, Jacobsen B, Hervig T, Engum A, Apelseth TO, et al. Transfusion reactions after whole blood transfusion in Norway, 2021–2024: A report from the Norwegian Hemovigilance program. Transfusion. 2026;66(6):1099-1107. doi:10.1111/trf.70193

BibTeX
@article{Erikstein2026,
  author = {Erikstein, Bjarte Skoe and Titze, Thomas Larsen and Jacobsen, Barbora and Hervig, Tor and Engum, Are and Apelseth, Torunn Oveland and Flesland, Øystein},
  title = {Transfusion reactions after whole blood transfusion in Norway, 2021–2024: A report from the Norwegian Hemovigilance program},
  journal = {Transfusion},
  year = {2026},
  volume = {66},
  number = {6},
  pages = {1099--1107},
  doi = {10.1111/trf.70193}
}
Kostenlos starten →